ClinicalTrials.gg
Status unknownNCT04385550Updated May 13, 2020

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

A Phase 3 interventional study of Anlotinib hydrochloride capsule and AK105 injection in Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 45 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-13.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.

02

Conditions studied

  • Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Understood and signed an form; 2. (ECOG) performance status score of 0 or 1; ≥ 3 months; 3. Histopathology or cytology confirmed as or local advanced gastric and gastro-oesophageal junction adenocarcinoma; 4. standard chemotherapy regimen in patients with advanced gastric or gastroesophageal junction adenocarcinoma after treatment failure; 5. Has at least one ; 6. Weight ≥40 kg or ≥18.5; 7. Adequate organ function; 8. Male or female subjects should agree to use an adequate method of starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.

Exclusion criteria

Exclusion Criteria:

    1. Histopathology confirmed as squamous cell carcinoma, carcinoid, undifferentiated carcinoma, or other gastric cancer; 2. positive; 3. Has received paclitaxel or docetaxel in the treatment; 4. Has received paclitaxel or docetaxel in the or adjuvant treatment regimen and have or metastasized within 6 months after the last dose; 5. Has other malignant tumors within 5 years; 6. Has used anti-angiogenic drugs such as anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, bevacizumab, or related immunotherapy drugs for , PD-L1, etc; 7. Severe after administration of other monoclonal antibodies; 8. Has spinal cord compression, cancerous meningitis and symptomatic ; 9. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1; 10. Has received radiotherapy, chemotherapy and surgery within 4 weeks before the first dose; 11. Has gastrointestinal bleeding tendency within 4 weeks before the first dose; 12. The tumor has invaded important blood vessels and will cause fatal bleeding; 13. Has multiple factors affecting oral medication; 14. Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 15. Has any active disease or history of autoimmune disease; 16. or systemic or absorbable local hormone therapy is required to achieve the aim of immunosuppression (dose > 10mg/ day prednisone or other therapeutic hormones) and is still used within 2 weeks after the first administration; 17. Has any serious and / or uncontrolled disease; 18. Has active viral infection; 19. Has participated in other anticancer drug clinical trials within 4 weeks; 20. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
528 participants (estimated)

Study arms

  • Experimental
    Anlotinib hydrochloride capsule + AK105 injection

    Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.

    Drug: Anlotinib hydrochloride capsule · Drug: AK105 injection

  • Active comparator
    Standard Second-line Chemotherapy

    Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.

    Drug: Paclitaxel injection · Drug: Docetaxel injection

Interventions

  • Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

  • AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.

  • Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.

  • Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 45 weeks

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 45 weeks

  2. Overall response rate (ORR)

    Percentage of subjects achieving complete response (CR) and partial response (PR).

    Time frame: up to 45 weeks

  3. Disease control rate (DCR)

    Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 45 weeks

  4. Duration of response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

    Time frame: up to 45 weeks

07

Study locations

45 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    • Kangsheng Gu, Doctor · Contact
    • Kangsheng Gu, Doctor · Principal investigator
  • Beijing Shijitan Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100038, China
    • Jirun Peng, Doctor · Contact1446316766@qq.com
    • Jirun Peng, Doctor · Principal investigator
  • The Sixth Medical Center of PLA General Hospital
    Beijing, Beijing 100048, China
    • Xinhong Zhang, Doctor · Contactzhangxh1970@sina.com
    • Xinhong Zhang, Doctor · Principal investigator
  • Peking University Shougang Hospital
    Beijing, Beijing 100144, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, Beijing 101100, China
    • Dong Yan, Doctor · Contactyd15yt88@163.com
    • Dong Yan, Doctor · Principal investigator
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing 102218, China
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350011, China
    • Zengqing Guo · Contact
    • Zengqing Guo · Principal investigator
  • Quanzhou First Hospital
    Quanzhou, Fujian 362000, China
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, Fujian 362000, China
    • Tianwen Xu, Doctor · Contactxutianwen53@163.com
    • Tianwen Xu, Doctor · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
    • Zhijie Ding, Doctor · Contactzhijieding@sina.com
    • Zhijie Ding, Doctor · Principal investigator
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
    • Xiaoming Hou, Doctor · Contact1795950416@qq.com
    • Xiaoming Hou, Doctor · Principal investigator
  • Gansu Wuwei Tumour Hospital
    Wuwei, Gansu 733000, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510000, China
    • Ruihua Xu, Doctor · Contactruihxu@163.com
    • Ruihua Xu, Doctor · Principal investigator
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510610, China
    • Yanhong Deng, Doctor · Contact
    • Yanhong Deng, Doctor · Principal investigator
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524000, China
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi Zhuang Autonomous Region 530021, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050010, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150040, China
    • Yanqiao Zhang, Doctor · Contactyanqiaozhang@126.com
    • Yanqiao Zhang, Doctor · Principal investigator
  • AnYang Tumor Hospital
    Anyang, Henan 455000, China
  • Xinxiang Central Hospital
    Xinxiang, Henan 453000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450003, China
    • Yanru Qin, Doctor · Contactyanruqin@163.com
    • Yanru Qin, Doctor · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    • Huijuan Wu · Contact
    • Huijuan Wu · Principal investigator
  • Union Hospital,Tongji Medical College,Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    • Tao Zhang, Doctor · Contact1277577866@qq.com
    • Tao Zhang, Doctor · Principal investigator
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
    • Xianglin Yuan, Doctor · Contactxlyuan1020@163.com
    • Xianglin Yuan, Doctor · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    • Xinjun Liang, Doctor · Contactdoctorlxj@163.com
    • Xinjun Liang, Doctor · Principal investigator
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    • Hongliang Yao, Doctor · Contactyaohl0326@163.com
    • Hongliang Yao, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    • Jianwei Lu, Doctor · Contactlujw@medmail.com.cn
    • Jianwei Lu, Doctor · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    • Lingjun Zhu, Doctor · Contact
    • Lingjun Zhu, Doctor · Principal investigator
  • Nantong Cancer Hospital
    Nantong, Jiangsu 226361, China
    • Jianhong Wang · Contactywk_wjh@163.com
    • Jianhong Wang · Principal investigator
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Hospital of Jiangnan University
    Wuxi, Jiangsu 214062, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Liaoning Cancar Hospital
    Shenyang, Liaoning 110042, China
    • Baoli Qin, Doctor · Contactporyqin@126.com
    • Baoli Qin, Doctor · Principal investigator
  • People's Hospital of Ningxia Hui Autonomous Region
    Yinchuan, Ningxia Hui Autonomous Region 750021, China
    • Qingxin Zhuang · Contactzhuangtse@163.com
    • Qingxin Zhuang · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    • Changzheng Li · Contactliczdoc@163.com
    • Changzheng Li · Principal investigator
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710004, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
  • Tianjin Medical University General Hospital
    Tianjing, Tianjing 300050, China
    • Diansheng Zhong, Doctor · Contactzhongdsh@hotmail.com
    • Diansheng Zhong, Doctor · Principal investigator
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjing, Tianjing 300060, China
    • Yi Ba, Doctor · Contactyiba99@yahoo.com
    • Yi Ba, Doctor · Principal investigator
  • The First People's Hospital of kashi region
    Kashi, XinJiang Uighur Autonomous Region 844000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2020; primary completion for Oct 2023, 41 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2020
First posted
May 13, 2020
StartEst.
May 20, 2020
Primary completionEst.
Oct 31, 2023
CompletionEst.
Dec 31, 2023
Last update
May 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04385550
Responsible party
Sponsor
First posted
May 13, 2020
Start date
May 20, 2020 (estimated)
Primary completion
Oct 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
May 13, 2020

Study contacts

Ruihua Xu
Contact
ruihxu@163.com
020-87343468

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Catequentinib hydrochloride · Penpulimab

Start the discussion